(ELV) Elevance Health Inc. Bundle
What does Elevance Health do?
Elevance Health, Inc. is a U.S. health benefits and health services company listed on the New York Stock Exchange under the ticker ELV. Its operating model combines Blue Cross and Blue Shield health plans, government program coverage, employer administrative services, pharmacy benefits, and clinical services. The company describes itself as focused on integrated whole-health solutions across the care journey in its 2025 Form 10-K, and that framing matters because Elevance is no longer only a traditional insurer.
Why is the business broader than health insurance?
The core Health Benefits segment sells and administers medical coverage for individuals, employers, Medicaid programs, Medicare members, and the Federal Employee Program. CarelonRx adds pharmacy benefit management, home delivery, specialty pharmacy, formulary management, rebates, claims adjudication, and infusion services. Carelon Services adds care delivery, behavioral health, analytics, payment integrity, home health, and complex care capabilities. The company’s public identity also emphasizes improving outcomes, lowering costs, and simplifying experiences through a whole-health model on its official approach to health page.
How does Elevance Health make money?
Elevance earns operating revenue through three main streams: premiums from risk-based health plans, product revenue mainly tied to pharmacy activities, and service fees from administrative and health-service arrangements. In the quarter ended March 31, 2026, the company reported $49.5B of operating revenue: $41.0B from premiums, $6.2B from product revenue, and $2.2B from service fees in its Q1 2026 Form 10-Q.
Which revenue stream drives the model?
Premiums dominate the revenue base because risk-based health plans collect fixed premiums and then pay medical claims. That creates the central financial tension: pricing, risk adjustment, quality scores, and medical cost trend must be accurate enough to leave an underwriting margin after claims. Service-fee arrangements are lower-risk because self-funded employer customers retain claim risk while Elevance earns administrative fees. Pharmacy and Carelon revenue add scale, but the economics depend on prescription volumes, specialty drug mix, rebate administration, and the cost of products sold.
| Revenue logic | Where it appears | Q1 2026 figure | Why it matters |
|---|---|---|---|
| Risk-based premiums | Commercial risk, Medicaid, Medicare, FEP, Individual | $41.0B premiums | Claims cost trend and pricing accuracy directly affect margins. |
| Pharmacy product revenue | CarelonRx | $6.2B product revenue | Specialty drug mix and prescription economics shape product margin. |
| Administrative and service fees | Fee-based employer plans and Carelon Services | $2.2B service fees | Fees diversify the model away from pure insurance underwriting risk. |
Which segments and member groups matter most?
Health Benefits is the economic center because it carries the membership base, premium revenue, medical-cost risk, and Blue brand distribution. CarelonRx and Carelon Services are strategically important because they can improve claims management, pharmacy economics, clinical engagement, and service revenue. Segment analysis must be read carefully because intersegment eliminations are large: Carelon can sell to Elevance-affiliated health plans as well as external customers.
How is the Health Benefits book mixed?
In 2025, Health Benefits operating revenue was $167.1B. Medicaid was the largest reported line at $56.6B, followed by Commercial at $50.4B, Medicare at $44.8B, and the Federal Employee Program at $15.3B. That mix explains why Elevance is sensitive to state Medicaid rate adequacy, Medicare Advantage quality and risk-adjustment rules, employer-group fee business, and commercial pricing discipline.
Which member categories explain scale?
| Segment | Q1 2026 operating revenue | Q1 2026 operating gain | Q1 2026 operating margin | Analytical interpretation |
|---|---|---|---|---|
| Health Benefits | $42.5B | $2.2B | 5.1% | Largest revenue base; margin depends on medical cost trend, pricing, risk adjustment, and membership mix. |
| CarelonRx | $10.6B | $0.6B | 5.5% | Pharmacy scale is meaningful, but lower adjusted script volume and product cost pressure matter. |
| Carelon Services | $7.4B | $0.5B | 6.4% | Service expansion supports whole-health strategy and can diversify revenue beyond insurance premiums. |
What did Elevance Health’s latest quarter show?
The latest official reporting period shows modest operating revenue growth, better operating cash flow, continued medical-cost pressure, and a significant regulatory accrual. Elevance reported Q1 2026 results on April 22, 2026; the company’s Q1 2026 earnings release said operating revenue rose 1.5% year over year to $49.5B, while adjusted diluted EPS was $12.58.
What changed in Q1 2026?
The quarter was not a simple growth story. The benefit expense ratio increased to 86.8%, up 40 basis points year over year, indicating claims cost pressure relative to premium revenue. The operating expense ratio rose to 12.8%, largely because Elevance recorded a $935M accrual connected to a Centers for Medicare & Medicaid Services matter and a $129M business optimization charge. Excluding adjusted items, the adjusted operating expense ratio was 10.5%, down 20 basis points.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Operating revenue | $49.5B | $48.8B | Growth was positive but modest, supported by commercial, Medicaid, and FEP revenue. |
| Shareholders’ net income | $1.8B | $2.2B | GAAP earnings were pressured by the CMS-related accrual and optimization charges. |
| Benefit expense ratio | 86.8% | 86.4% | Higher ratio signals more premium dollars consumed by benefits. |
| Days in claims payable | 46.6 days | 42.8 days | Higher days payable can reflect timing, claims receipt patterns, and reserve dynamics. |
| Medical membership | 45.4M | 45.8M | Total medical membership declined 0.9%, with Medicaid, Medicare Advantage, FEP, and risk-based employer declines partly offset by fee-based employer growth. |
How financially strong is Elevance Health?
Elevance’s financial profile combines very large revenue scale with thin healthcare underwriting margins, meaningful debt, recurring dividends and buybacks, and large claims liabilities. In FY2025, the company reported $197.6B of operating revenue, $5.7B of shareholders’ net income, and $4.3B of operating cash flow. In Q1 2026, operating cash flow improved to $4.3B, up $3.3B from Q1 2025.
How do cash flow, debt, and capital returns fit together?
The cash-flow bridge is central to valuation. Free cash flow can be approximated as operating cash flow minus capital expenditures; on that basis, FY2025 operating cash flow of $4.3B less $1.1B of property and equipment purchases implies roughly $3.2B before other investing and financing choices. Q1 2026 was stronger on operating cash flow, but the company also returned $1.5B to shareholders through $1.1B of repurchases and $376M of dividends.
| Financial item | FY2025 or Q1 2026 value | Why it matters |
|---|---|---|
| Cash and equivalents | $9.7B at March 31, 2026 | Supports claims timing, regulatory capital, acquisitions, dividends, and repurchases. |
| Medical claims payable | $18.4B at March 31, 2026 | Shows the scale of unsettled medical obligations and reserve-estimation sensitivity. |
| Long-term debt | $31.1B at March 31, 2026, including current portion | Debt capacity matters because margins are thin and regulated health businesses need liquidity. |
| Shareholders’ equity | $43.9B at March 31, 2026 | Equity base provides a cushion against claims, regulatory, and capital-allocation shocks. |
| Remaining buyback authorization | $5.6B at March 31, 2026 | Repurchases can support per-share growth when cash generation and valuation allow. |
What turning points shaped Elevance Health’s strategy?
Elevance’s current model is the result of scale-building, Blue plan consolidation, a strategic rebranding, and a shift toward services through Carelon. The history matters because it explains why the company has both local-market insurance strengths and a national platform for pharmacy and care services.
-
2004Anthem and WellPoint completed a merger valued at approximately $16.5B, according to the official merger completion release. The transaction expanded Blue-branded scale and helped create the footprint behind today’s Health Benefits business.
-
2017Gail K. Boudreaux became president and chief executive officer, a leadership change that still anchors the company’s current governance and strategic execution profile.
-
2022Shareholders approved the corporate rebrand from Anthem to Elevance Health, signaling a strategic identity broader than insurance and tied to whole health, digital capabilities, and services.
-
2024Paragon Healthcare added ambulatory infusion centers to CarelonRx, strengthening the company’s specialty pharmacy and site-of-care capabilities.
-
2024The CareBridge acquisition expanded Carelon Services, supporting home and community-based care exposure and helping explain Carelon Services revenue growth in FY2025.
-
2026The Operating Model Transformation Program began in Q1 2026 to simplify structures, modernize technology, and use advanced technologies including AI, while the CMS matter became a major regulatory watch item.
What strategic tension does this history create?
What gives Elevance Health a competitive advantage?
Elevance competes in a highly regulated and highly competitive managed-care market. Its advantage is not a single asset; it is the combination of Blue Cross and Blue Shield brand rights in important local markets, provider network scale, government-program experience, employer relationships, pharmacy infrastructure, and the ability to use Carelon capabilities to manage cost and complexity.
Why do Blue licenses and local networks matter?
The 2025 Form 10-K states that Elevance is an independent licensee of the Blue Cross Blue Shield Association in multiple states and holds licensed insurance operations across all 50 states. In managed care, local provider contracts and brand trust affect unit costs, network attractiveness, and the ability to win employer and government business. Elevance also competes on quality ratings, product breadth, digital capabilities, service, reputation, and financial stability.
Which competitors pressure the business?
The company’s own filings describe competition from national and regional managed-care organizations, provider-sponsored plans, administrative service providers, government program bidders, pharmacy service providers, retail pharmacies, web pharmacies, specialty pharmacies, and new technology-enabled models. This is a rivalry-heavy industry: competitors can pressure premiums, provider terms, pharmacy economics, quality ratings, and digital expectations at the same time.
Who owns Elevance Health stock, and why does governance matter?
Elevance has one class of common stock with one vote per share, so governance is not shaped by founder super-voting control. Instead, the investor profile is influenced by large passive institutional holders, an independent board, executive incentives, and capital-allocation discipline. The latest 2026 proxy statement reported 219.7M common shares outstanding and entitled to vote as of the March 13, 2026 record date.
What does the ownership profile signal?
| Holder or governance group | Reported ownership or structure | Source period | Why it matters |
|---|---|---|---|
| The Vanguard Group | 22.9M shares, 10.1% | Schedule 13G/A cited in 2026 proxy | Large passive holder influence makes governance quality and capital allocation important. |
| BlackRock, Inc. | 17.7M shares, 7.8% | Schedule 13G/A cited in 2026 proxy | Another major institutional owner; voting outcomes are institutionally influenced. |
| Directors and executive officers as a group | 799,910 shares beneficially owned | February 1, 2026 | No current director or executive officer group member owns more than 1%, so control is dispersed. |
| Board independence | 11 of 12 directors independent | 2026 proxy | Independence is relevant in a company with regulatory risk, complex claims estimates, and large capital returns. |
| Leadership structure | Separate CEO and independent Board Chair | 2026 proxy | Separating roles can strengthen oversight of strategy, risk, and executive performance. |
For investors, this means Elevance is best analyzed as a large-cap institutionally governed company rather than a controlled founder company. Shareholder returns through dividends and buybacks matter, but they must be balanced against regulated-capital needs, medical claims reserves, debt capacity, and reputational trust.
What risks and opportunities could change Elevance Health’s outlook?
Elevance’s opportunity set is tied to cost control, government program execution, Carelon growth, pharmacy services, digital modernization, and fee-based employer scale. Its risk profile is equally specific: medical cost trend, Medicaid rate adequacy, Medicare Advantage rules, Star Ratings, CMS risk-adjustment issues, provider contracts, pharmacy pricing, cyber risk, and the terms of Blue Cross Blue Shield licensing can all affect earnings quality.
Which risk appears most material in the latest filing?
The Q1 2026 Form 10-Q describes a CMS notice involving alleged noncompliance with certain Medicare Advantage risk-adjustment data submission requirements. Elevance accrued approximately $935M as its current best estimate of potential exposure for resubmission of certain Medicare Advantage risk-adjustment data for dates of service from 2015 through April 2, 2023. The same filing says the possible liability range could be approximately $585M less than the accrued amount to $565M above it, which makes the matter both financially and reputationally important.
Where are the strategic opportunities?
The opportunity side is not only member growth. Elevance can improve value through better risk selection, more accurate pricing, stronger Medicaid and Medicare contract execution, care management, pharmacy integration, specialty and infusion services, technology modernization, and administrative simplification. The Operating Model Transformation Program is important because the company is trying to lower complexity while using advanced technologies and modernized systems to improve cost, speed, and service quality.
| Risk or opportunity | Officially visible signal | Financial line affected | What to monitor |
|---|---|---|---|
| Medical cost trend | Q1 2026 benefit expense ratio of 86.8% | Benefit expense, operating gain | Premium pricing versus claims trend in Medicaid, commercial, and Medicare. |
| CMS and Medicare Advantage compliance | $935M Q1 2026 accrual | Operating expense, cash flow, reputation | Compliance milestones, litigation updates, and Star Ratings. |
| Carelon services growth | Q1 2026 Carelon Services revenue of $7.4B | Service fees, operating margin | External customer wins, integration, and margin durability. |
| Pharmacy economics | CarelonRx revenue of $10.6B in Q1 2026 | Product revenue, cost of products sold | Adjusted scripts, specialty mix, rebates, and pricing pressure. |
Which KPIs best explain Elevance Health’s performance?
The most useful KPIs are not generic revenue and EPS alone. Elevance requires a managed-care dashboard: medical membership by category, premium revenue growth, benefit expense ratio, medical claims payable, days in claims payable, CarelonRx scripts, Carelon Services consumers served, operating cash flow, debt, and capital returns. These metrics connect operating execution to valuation.
Why are these KPIs more useful than a simple revenue chart?
Revenue can rise while margins weaken if medical costs are underpriced or government program rates lag claims trend. Conversely, membership can decline while profitability improves if lower-margin categories shrink and pricing catches up. For Elevance, the best analytical habit is to connect each KPI to a financial statement line: membership to premiums and service fees, benefit expense ratio to claims, days in claims payable to reserves, scripts to product revenue and cost of products sold, and operating cash flow to capital allocation.
Why does Elevance Health matter for valuation?
A DCF or comparable-company analysis for Elevance should not treat the company like a high-margin software platform or a simple cyclical business. The right valuation questions are about premium growth, medical-cost trend, government-program stability, Carelon margin contribution, cash conversion, leverage, and how much capital can be returned without weakening the regulated balance sheet.
What valuation drivers should a student model?
The most defensible model begins with operating revenue by segment, then estimates benefit expense ratio, operating expense ratio, Carelon margins, tax rate, capital expenditures, working-capital and claims-reserve movements, debt service, and share count. Per-share value is especially sensitive to buybacks because Elevance repurchased 3.7M shares in Q1 2026 and had 217.4M common shares outstanding at March 31, 2026.
| Valuation driver | Relevant Elevance metric | Modeling implication |
|---|---|---|
| Revenue growth | Q1 2026 operating revenue +1.5% year over year | Segment and category mix matter more than headline growth alone. |
| Underwriting margin | Q1 2026 benefit expense ratio 86.8% | Small ratio changes can materially affect operating income. |
| Services contribution | Q1 2026 Carelon Services margin 6.4% | Carelon growth can diversify the earnings base if margins hold. |
| Capital returns | $1.5B returned in Q1 2026 | Buybacks and dividends affect per-share compounding and cash retained. |
| Regulatory shock risk | $935M CMS-related accrual in Q1 2026 | Scenario analysis should include adverse regulatory and cash-payment outcomes. |
What is the key takeaway from Elevance Health analysis?
Elevance Health is important because it combines one of the largest U.S. medical membership bases with Blue brand distribution, government-program exposure, pharmacy infrastructure, and a growing health-services platform. The company’s story is supported by scale, fee-based employer membership, Carelon integration, operating cash flow, and an institutionally governed board structure. The story is pressured by claims-cost inflation, Medicaid and Medicare Advantage execution, CMS and risk-adjustment scrutiny, pharmacy economics, and the need to keep trust with members, providers, regulators, and employers.
The central analytical question is whether Elevance can convert healthcare scale into durable cash flow while controlling medical costs and regulatory risk. A strong analysis should track benefit expense ratio, membership mix, Carelon margins, operating cash flow, claims reserves, Medicare Advantage quality metrics, the CMS matter, and capital returns. The company is not best understood through revenue size alone; it is best understood through the interaction between insurance underwriting, pharmacy and care services, regulatory compliance, and disciplined capital allocation.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.